Bullish & Foolish
--
--

Is Hyperion Defi going out of business?

Loading the full analysis
Reading the filings

HYPERION DEFI, INC. (HYPD) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

HYPERION DEFI, INC. (HYPD) scores 25 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 25/100
Rating Distressed / Caution
Sector Biotech/Pharma
Market cap $51.3M
Last close $3.30
Revenue growth (YoY) 2317.3%
Dividend yield 0.0%

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (334.0% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Critical
3-6 mo of estimated runway from 2026-06-30, based on $9.6M of cash and short-term investments against $26.1M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.
Business quality - Pre-commercial
Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.
Trajectory - Clinical progress unavailable
Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.
Valuation - Demanding
-19.5% net-cash backing support a demanding pre-commercial Valuation assessment.
Event risk - Critical event risk
Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

  • Shares dilution YoY: Reverse split detected; adjusted share change (334.0% YoY) and the capital-structure risk is penalized.
  • Debt / Equity: -0.03x (Net Cash)
  • ROIC: -46.99%
  • Filing event risk: Going-Concern Warning (-8 pts)
  • R&D intensity: 88.40%
  • Return on Assets: -40.05%
  • Asset Growth Velocity: 103.27% YoY (Aggressive buildout)
  • Debt Maturity Runway: 100% long-term (Long-term focused)
  • Revenue growth YoY: 2329.98% (YoY) - Early-Stage Surge (low base)
  • Interest coverage: 3.7x
  • Price / Sales: 70.1x (see Valuation)
  • Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-07.

Headline score detail

Source coverage and limitations
--
Reference Links